FS222, a CD137/PD-L1 Tetravalent Bispecific Antibody, Designed for Optimal CD137 Engagement Resulting in Potent Conditional T-Cell Activity
Year: 2025
Type: article
Source: Current Cancer Drug Targets
Authors: Matthew A. Lakins, Christel Séguy Veyssier, Jose Munoz-Olaya, Emma Goodman, Robert Hughes, James J Day, Quincy Kaka, Jennifer Ofoedu, Ryan Fiehler, Daniel Jones, Michelle Morrow, Neil Brewis
Institution: F-star (United Kingdom)
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4414981640
FWCI:
Cites:
Cited by:
Related to: